Page last updated: 2024-10-19

niacinamide and Weight Gain

niacinamide has been researched along with Weight Gain in 19 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Weight Gain: Increase in BODY WEIGHT over existing weight.

Research Excerpts

ExcerptRelevanceReference
"We investigated the change of tryptophan-niacin metabolism in rats with puromycin aminonucleoside PAN-induced nephrosis, the mechanisms responsible for their change of urinary excretion of nicotinamide and its metabolites, and the role of the kidney in tryptophan-niacin conversion."7.73Tryptophan-niacin metabolism in rat with puromycin aminonucleoside-induced nephrosis. ( Egashira, Y; Nagaki, S; Sanada, H, 2006)
"Ecological evidence suggests that niacin (nicotinamide and nicotinic acid) fortification may be involved in the increased prevalence of obesity and type 2 diabetes, both of which are associated with insulin resistance and epigenetic changes."3.79Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. ( Cao, JM; Cao, Y; Gong, XJ; Guo, J; Guo, M; Li, D; Lun, YZ; Luo, N; Sun, WP; Tian, YJ; Zhou, SS, 2013)
"We investigated the change of tryptophan-niacin metabolism in rats with puromycin aminonucleoside PAN-induced nephrosis, the mechanisms responsible for their change of urinary excretion of nicotinamide and its metabolites, and the role of the kidney in tryptophan-niacin conversion."3.73Tryptophan-niacin metabolism in rat with puromycin aminonucleoside-induced nephrosis. ( Egashira, Y; Nagaki, S; Sanada, H, 2006)
" In the presence of excess dietary nicotinamide, chicks fed the corn-casein diet achieved maximal weight gain when 100 mg/kg of L-tryptophan was supplemented."3.68Quantitative efficacy of niacin sources for chicks: nicotinic acid, nicotinamide, NAD and tryptophan. ( Baker, DH; Oduho, GW, 1993)
" As the result, the urinary excretion of Nam, N1-methyl-4-pyridone-3-carboxamide (4-Py), Nam + N1-methylnicotinamide (MNA) + N1-methyl-2-pyridone-5-carboxamide (2-Py) + 4-Py was lower in the CCl4-treated groups than in the non-treated group (control) regardless of the experimental period (1 mo and 2 mo) or dosing amount of CCl4 (0."1.30Tryptophan-niacin metabolism in liver cirrhosis rat caused by carbon tetrachloride. ( Egashira, Y; Isagawa, A; Komine, T; Ohta, T; Sanada, H; Shibata, K; Yamada, E, 1999)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (31.58)18.2507
2000's8 (42.11)29.6817
2010's4 (21.05)24.3611
2020's1 (5.26)2.80

Authors

AuthorsStudies
Méndez-Lara, KA1
Rodríguez-Millán, E1
Sebastián, D1
Blanco-Soto, R1
Camacho, M1
Nan, MN1
Diarte-Añazco, EMG1
Mato, E1
Lope-Piedrafita, S1
Roglans, N1
Laguna, JC1
Alonso, N1
Mauricio, D1
Zorzano, A1
Villarroya, F1
Villena, JA1
Blanco-Vaca, F1
Julve, J1
Li, D1
Tian, YJ1
Guo, J1
Sun, WP1
Lun, YZ1
Guo, M1
Luo, N1
Cao, Y1
Cao, JM1
Gong, XJ1
Zhou, SS1
Ying, HZ1
Zang, JN1
Deng, LL1
Wang, ZY1
Yu, CH1
Shibata, K8
Imai, S1
Nakata, C1
Fukuwatari, T3
Cantó, C1
Houtkooper, RH1
Pirinen, E1
Youn, DY1
Oosterveer, MH1
Cen, Y1
Fernandez-Marcos, PJ1
Yamamoto, H1
Andreux, PA1
Cettour-Rose, P1
Gademann, K1
Rinsch, C1
Schoonjans, K1
Sauve, AA1
Auwerx, J1
Wada, H1
Sasaki, R2
Lo, HC1
Tu, ST1
Lin, KC1
Lin, SC1
Takahashi, C1
Egashira, Y2
Nagaki, S1
Sanada, H2
Nakamura, T1
Terajima, T1
Ogata, T1
Ueno, K1
Hashimoto, N1
Ono, K1
Yano, S1
Goestemeyer, AK1
Marks, J1
Srai, SK1
Debnam, ES1
Unwin, RJ1
Oduho, GW1
Baker, DH1
Mushiage, M1
Kondo, T3
Hayakawa, T1
Tsuge, H1
Shimada, H2
Taguchi, H1
Marugami, M1
Umezawa, C1
Isagawa, A1
Komine, T1
Yamada, E1
Ohta, T1
Mokudai, T1
Ayoub, IA2
Sakakibara, Y1
Lee, EJ1
Ogilvy, CS1
Maynard, KI2

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Validation of an Enzymatic Assay for Quantification of Nicotinamide Adenine Dinucleotide in Blood Plasma After Ingestion of the Vitamin B3 Variant Nicotinamide Riboside: a Randomized Controlled Trial[NCT06005350]54 participants (Anticipated)Interventional2023-11-01Recruiting
Vitamin B3 as a Novel Mitochondrial Therapy for Obesity[NCT03951285]56 participants (Actual)Interventional2016-05-25Completed
Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy[NCT03642990]Phase 25 participants (Actual)Interventional2019-11-08Terminated (stopped due to Enrollment challenges)
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity[NCT02812238]38 participants (Actual)Interventional2016-06-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Difference in Score Between Baseline and End of Treatment for the FACT&GOG-NTX Subscale .

Difference in Score on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity questionnaire at the end of treatment; i.e. Score at screening - score at end of treatment. This questionnaire asks 11 questions that are specific to chemotherapy-induced peripheral neuropathies. Maximum score is 44, minimum score is 0. Positive differences indicate a decrease in neuropathy. Negative differences indicate a worsening of neuropathy. Zero means unchanged. (NCT03642990)
Timeframe: 4 weeks

Interventionunits on a scale (Median)
NIAGEN®)7

Difference in Total Neuropathy Score Between Screening and End of Treatment

Exploratory analysis of ability of the clinical version of the Total Neuropathy Score questionnaire to detect changes in CIPN severity over time. Unlike the CTCAE or the FACT&GOG-NTX questionnaires, the TNS is a patient reported outcome measure. HIghest score (worse neuropathy is 24, lowest score is 0. Outcome assessed difference between end of treatment and screening. A positive number indicates improvement in neuropathy (NCT03642990)
Timeframe: 4 weeks

Interventionscore on a scale (Median)
NIAGEN®)2

Number of Dose Reduction Events

Count the number of (i.e. the incidence) of dose reduction events due to neuropathy (each occasion of dose reduction is a separate event); (NCT03642990)
Timeframe: 3 weeks

Interventionevent (Number)
NIAGEN®)0

Number of Participants With No Worsening in the Grade of Peripheral Sensory Neuropathy as Scored by CTCAE

"The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe symptoms that limit self-care activities of daily living. Because the outcome measure is defined as no worsening of the grade, it was recorded as either yes( i.e. it worsened) or no (i.e. it did not worsen)." (NCT03642990)
Timeframe: approximately 4 weeks

InterventionParticipants (Count of Participants)
NIAGEN®)3

Percentage of Patients in Which Dose of Paclitaxel or Nab-Paclitaxel is Reduced Due to CIPN

Quantitate the percentage of patients that experience a dose reduction of paclitaxel or nab-paclitaxel therapy due to neuropathy. (NCT03642990)
Timeframe: 3 weeks

InterventionParticipants (Count of Participants)
NIAGEN®)0

Plasma Concentration of Paclitaxel After NIAGEN Treatment Began

Paclitaxel levels in plasma were measured ~30 min after each infusion of taxane. This was undertaken to ascertain whether NIAGEN altered plasma levels of paclitaxel because increases or decreases in plasma levels of paclitaxel by itself could lead to an apparent worsening or improvement, respectively, in CIPN and confound interpretation of NIAGEN's effect. (NCT03642990)
Timeframe: up to 3 weeks

Interventionng/ml (Median)
NIAGEN®)810

Total Dose of Paclitaxel Administered

Quantitate the total cumulative dose of paclitaxel administered over the 12 weeks. (NCT03642990)
Timeframe: 3 weeks

Interventionmg/M^2 (Number)
NIAGEN®)200

Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast

The IL- 1beta secretion is measured in response to fasting, refeeding and administration of Nicotinamide Riboside (or placebo). Nicotinamide riboside acts as a fasting mimetic, and is supposed to maintain the reduction of IL-1 beta secretion (indicating NLRP3 inflammasome activation) induced by fasting. 1000 mg of Nicotinamide riboside on a daily basis is given to the subjects for a period of 7-10 days. (NCT02812238)
Timeframe: 4 weeks

Interventionmg/dL (Mean)
Nicotinamide Riboside582
Placebo794

Other Studies

19 other studies available for niacinamide and Weight Gain

ArticleYear
Nicotinamide Protects Against Diet-Induced Body Weight Gain, Increases Energy Expenditure, and Induces White Adipose Tissue Beiging.
    Molecular nutrition & food research, 2021, Volume: 65, Issue:11

    Topics: Adipocytes, Beige; Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Anim

2021
Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats.
    The British journal of nutrition, 2013, Volume: 110, Issue:12

    Topics: Animals; Betaine; Choline; CpG Islands; Dietary Supplements; DNA; DNA Damage; DNA Methylation; Epige

2013
Pentamethylquercetin reduces fat deposition via Sirt1-mediated pathways in male obese mice induced by a high fat diet.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2013, Volume: 62

    Topics: Adipogenesis; Adipose Tissue; Adipose Tissue, White; Animals; Diet, High-Fat; Gene Expression Regula

2013
The effects of glycine, L-threonine, and L-cystine supplementation to a 9% casein diet on the conversions of L-tryptophan to nicotinamide and to serotonin in rats.
    Journal of nutritional science and vitaminology, 2013, Volume: 59, Issue:6

    Topics: Animals; Body Weight; Caseins; Cystine; Diet; Dietary Supplements; Glycine; Male; Models, Animal; Ni

2013
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
    Cell metabolism, 2012, Jun-06, Volume: 15, Issue:6

    Topics: Acetylation; Adipose Tissue, Brown; Animals; Brain; Diet, High-Fat; Dietary Supplements; Electron Tr

2012
Effects of excess nicotinamide administration on the urinary excretion of nicotinamide N-oxide and nicotinuric acid by rats.
    Bioscience, biotechnology, and biochemistry, 2004, Volume: 68, Issue:1

    Topics: Animals; Dose-Response Relationship, Drug; Eating; Liver; Male; NAD; NADP; Niacinamide; Nicotinic Ac

2004
The anti-hyperglycemic activity of the fruiting body of Cordyceps in diabetic rats induced by nicotinamide and streptozotocin.
    Life sciences, 2004, Apr-23, Volume: 74, Issue:23

    Topics: Administration, Oral; Animals; Blood Glucose; Cordyceps; Diabetes Mellitus, Experimental; Diet; Dise

2004
Effects of excess pantothenic acid administration on the other water-soluble vitamin metabolisms in rats.
    Journal of nutritional science and vitaminology, 2005, Volume: 51, Issue:6

    Topics: Animals; Ascorbic Acid; Diet; Eating; Energy Metabolism; Liver; Male; Niacin; Niacinamide; Organ Siz

2005
Tryptophan-niacin metabolism in rat with puromycin aminonucleoside-induced nephrosis.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 2006, Volume: 76, Issue:1

    Topics: Animals; Carboxy-Lyases; Kidney; Liver; Male; NAD; Nephrosis; Niacin; Niacinamide; Puromycin Aminonu

2006
Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozotocin and nicotinamide.
    Biological & pharmaceutical bulletin, 2006, Volume: 29, Issue:6

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Do

2006
GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-betal and plasma glucose concentration.
    Diabetologia, 2007, Volume: 50, Issue:10

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Enzyme Activation; Glucose Transporter Type

2007
Quantitative efficacy of niacin sources for chicks: nicotinic acid, nicotinamide, NAD and tryptophan.
    The Journal of nutrition, 1993, Volume: 123, Issue:12

    Topics: Analysis of Variance; Animal Feed; Animals; Biological Assay; Chickens; Dose-Response Relationship,

1993
Effects of vitamin B6 deficiency on the conversion ratio of tryptophan to niacin.
    Bioscience, biotechnology, and biochemistry, 1995, Volume: 59, Issue:11

    Topics: Animals; Diet; Feeding Behavior; Kynurenic Acid; Niacin; Niacinamide; Rats; Rats, Wistar; Tryptophan

1995
Fate of nicotinamide differs due to an intake of nicotinamide.
    Bioscience, biotechnology, and biochemistry, 1996, Volume: 60, Issue:7

    Topics: Animals; Biotransformation; Chromatography, High Pressure Liquid; Diet; Eating; Liver; Male; Niacina

1996
Increased conversion ratio of tryptophan to niacin by the administration of clofibrate, a hypolipidemic drug, to rats.
    Bioscience, biotechnology, and biochemistry, 1996, Volume: 60, Issue:9

    Topics: Animals; Clofibrate; Hypolipidemic Agents; Liver; Male; NAD; Niacin; Niacinamide; Rats; Rats, Wistar

1996
Effects of feeding tryptophan-limiting diets on the conversion ratio of tryptophan to niacin in rats.
    Bioscience, biotechnology, and biochemistry, 1996, Volume: 60, Issue:10

    Topics: Amino Acids; Animals; Caseins; Diet; Eating; Gelatin; Liver; Male; Niacin; Niacinamide; Rats; Rats,

1996
Tryptophan-niacin metabolism in liver cirrhosis rat caused by carbon tetrachloride.
    Journal of nutritional science and vitaminology, 1999, Volume: 45, Issue:4

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Carbon Tetrachloride; Liver Cirrhosis, E

1999
Delayed treatment with nicotinamide (Vitamin B(3)) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats.
    Stroke, 2000, Volume: 31, Issue:7

    Topics: Animals; Brain; Cerebral Infarction; Energy Metabolism; Ischemic Attack, Transient; Male; Motor Acti

2000
Therapeutic window for nicotinamide following transient focal cerebral ischemia.
    Neuroreport, 2002, Feb-11, Volume: 13, Issue:2

    Topics: Animals; Behavior, Animal; Cerebral Infarction; Drug Administration Schedule; Ischemic Attack, Trans

2002